Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of RUA.L is 50.0 and suggests 75.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc